Contents
pdf Download PDF
pdf Download XML
44 Views
15 Downloads
Share this article
Research Article | Volume 11 Issue 7 (July, 2025) | Pages 909 - 915
Evaluation of Association between Subclinical Hypothyroidism and Atherosclerosis As Measured By CIMT
 ,
 ,
 ,
 ,
 ,
 ,
 ,
 ,
1
Associate Professor, Dept Of General Medicine, Mahatma Gandhi Medical College And Hospital, Jaipur
2
Professor And HOD, Dept Of General Medicine, Mahatma Gandhi Medical College And Hospital, Jaipur
3
Resident 3rd Year, Dept Of General Medicine, Mahatma Gandhi Medical College And Hospital, Jaipur
4
Professor, Dept Of General Medicine, Mahatma Gandhi Medical College And Hospital, Jaipur
5
Assistant Professor, Dept Of General Medicine, Mahatma Gandhi Medical College And Hospital, Jaipur
Under a Creative Commons license
Open Access
Received
June 14, 2025
Revised
June 30, 2025
Accepted
July 16, 2025
Published
July 30, 2025
Abstract

Background: Thyroid dysfunction has been associated with cardiovascular disease. Subclinical hypothyroidism (SH), which is characterized by elevated thyroid stimulating hormone (TSH) levels and normal circulating free thyroid hormones is an independent risk factors for the pathogenesis of atherosclerosis and cardiovascular disease, affecting adversely the endothelial function. AIM: The aim of the study is to evaluate association between subclinical Hypothyroidism (SCH) and atherosclerosis as measured by CIMT. Methodology: A Cross Sectional Study conducted at Mahatma Gandhi Medical College & Hospital Jaipur Patients who are Diagnosed as Cases of Subclinical Hypothyroidism in Mahatma Gandhi Hospital on 130 patients who are divided into two groups-65 patients in Euthyroid group and 65 patients in Subclinical Hypothyroidism group. Result: Subclinical hypothyroidism was associated with significant dyslipidemia, elevated CRP, and increased CIMT, suggesting early atherosclerotic changes. However, conflicting findings in literature and the study's cross-sectional design limit causal inference. Conclusion: Subclinical hypothyroidism is associated with atherogenic dyslipidemia, elevated CRP, and increased CIMT, indicating a potential link to early atherosclerosis.

Keywords
INTRODUCTION

Thyroid disorders are among the most common endocrine problems worldwide, with an estimated 41 million people affected in India alone1. These disorders encompass a spectrum ranging from overt and subclinical hypothyroidism to overt and subclinical hyperthyroidism. Thyroid hormones play a critical role in regulating metabolism, including lipid metabolism, energy balance, and cardiovascular function. Hypothyroidism, especially in its subclinical form, is the most prevalent type, particularly among aging women. The metabolic disturbances associated with thyroid dysfunction, particularly subclinical hypothyroidism (SCH), have been increasingly linked to the development of atherosclerosis (AS), a leading cause of cardiovascular morbidity and mortality globally. Atherosclerosis is a chronic inflammatory disease of medium and large-sized arteries, characterized by lipid accumulation, thickening of the arterial wall, and plaque formation. The underlying mechanisms include oxidative stress, endothelial dysfunction, vascular remodeling, and immune cell infiltration2. Early in its course, AS may remain asymptomatic, but over time it can lead to significant complications such as myocardial infarction, stroke, and peripheral vascular disease. One of the early detectable changes associated with AS is the thickening of the arterial wall, best measured non-invasively using carotid intima-media thickness (CIMT)3. This marker is a widely accepted surrogate for early atherosclerosis and cardiovascular risk. Dyslipidemia is a primary driver of atherosclerosis. Elevated levels of total cholesterol, LDL cholesterol, and triglycerides, along with decreased HDL cholesterol4, are known to disrupt endothelial integrity and promote plaque formation. LDL particles, particularly when oxidized (ox-LDL), play a central role by attracting monocytes and transforming them into macrophages, which in turn become foam cells—hallmarks of early atherosclerotic plaques. Oxidative stress, often enhanced in hypothyroid states, promotes further inflammation and accelerates plaque instability. HDL, generally protective due to its role in reverse cholesterol transport, loses its anti-atherogenic properties when oxidized (ox-HDL), thus becoming pro-inflammatory and contributing to plaque rupture and thrombosis. Subclinical hypothyroidism, defined by elevated TSH with normal circulating thyroid hormones5, has been associated with an unfavorable lipid profile. Studies have consistently shown that individuals with SCH have higher levels of total cholesterol, LDL, and triglycerides, with lower levels of HDL. Moreover, inflammatory markers such as C-reactive protein (CRP) are elevated in SCH, indicating a low-grade inflammatory state that further contributes to vascular injury6,7. These metabolic and inflammatory alterations contribute to endothelial dysfunction, vascular stiffness, and increased CIMT—factors that collectively enhance cardiovascular risk. Several studies support the association between SCH and increased CIMT, reinforcing the hypothesis that SCH may promote early atherosclerosis. Therapeutic intervention with levothyroxine has demonstrated improvements in lipid profiles and reductions in CIMT, suggesting a potential benefit in treating SCH to prevent cardiovascular events8. However, not all studies agree, with some showing no significant relationship between TSH levels and CIMT, highlighting the complexity of the condition and the need for individualized treatment decisions9.

 

AIM

The aim of the study is to evaluate association between subclinical Hypothyroidism (SCH) and atherosclerosis as measured by CIMT.

Thyroid disorders are among the most common endocrine problems worldwide, with an estimated 41 million people affected in India alone1. These disorders encompass a spectrum ranging from overt and subclinical hypothyroidism to overt and subclinical hyperthyroidism. Thyroid hormones play a critical role in regulating metabolism, including lipid metabolism, energy balance, and cardiovascular function. Hypothyroidism, especially in its subclinical form, is the most prevalent type, particularly among aging women. The metabolic disturbances associated with thyroid dysfunction, particularly subclinical hypothyroidism (SCH), have been increasingly linked to the development of atherosclerosis (AS), a leading cause of cardiovascular morbidity and mortality globally. Atherosclerosis is a chronic inflammatory disease of medium and large-sized arteries, characterized by lipid accumulation, thickening of the arterial wall, and plaque formation. The underlying mechanisms include oxidative stress, endothelial dysfunction, vascular remodeling, and immune cell infiltration2. Early in its course, AS may remain asymptomatic, but over time it can lead to significant complications such as myocardial infarction, stroke, and peripheral vascular disease. One of the early detectable changes associated with AS is the thickening of the arterial wall, best measured non-invasively using carotid intima-media thickness (CIMT)3. This marker is a widely accepted surrogate for early atherosclerosis and cardiovascular risk. Dyslipidemia is a primary driver of atherosclerosis. Elevated levels of total cholesterol, LDL cholesterol, and triglycerides, along with decreased HDL cholesterol4, are known to disrupt endothelial integrity and promote plaque formation. LDL particles, particularly when oxidized (ox-LDL), play a central role by attracting monocytes and transforming them into macrophages, which in turn become foam cells—hallmarks of early atherosclerotic plaques. Oxidative stress, often enhanced in hypothyroid states, promotes further inflammation and accelerates plaque instability. HDL, generally protective due to its role in reverse cholesterol transport, loses its anti-atherogenic properties when oxidized (ox-HDL), thus becoming pro-inflammatory and contributing to plaque rupture and thrombosis. Subclinical hypothyroidism, defined by elevated TSH with normal circulating thyroid hormones5, has been associated with an unfavorable lipid profile. Studies have consistently shown that individuals with SCH have higher levels of total cholesterol, LDL, and triglycerides, with lower levels of HDL. Moreover, inflammatory markers such as C-reactive protein (CRP) are elevated in SCH, indicating a low-grade inflammatory state that further contributes to vascular injury6,7. These metabolic and inflammatory alterations contribute to endothelial dysfunction, vascular stiffness, and increased CIMT—factors that collectively enhance cardiovascular risk. Several studies support the association between SCH and increased CIMT, reinforcing the hypothesis that SCH may promote early atherosclerosis. Therapeutic intervention with levothyroxine has demonstrated improvements in lipid profiles and reductions in CIMT, suggesting a potential benefit in treating SCH to prevent cardiovascular events8. However, not all studies agree, with some showing no significant relationship between TSH levels and CIMT, highlighting the complexity of the condition and the need for individualized treatment decisions9.

 

AIM

The aim of the study is to evaluate association between subclinical Hypothyroidism (SCH) and atherosclerosis as measured by CIMT.

MATERIALS AND METHODS

A Cross Sectional Study conducted at Mahatma Gandhi Medical College & Hospital Jaipur Patients who are Diagnosed as Cases of Subclinical Hypothyroidism in Mahatma Gandhi Hospital on 130 patients who are divided into two groups-65 patients in Euthyroid group and 65 patients in Subclinical Hypothyroidism group. This study was conducted in MG Medical College & Hospital, Jaipur from July 2023 to December 2024 for a period of 1.5 years. It is an observational case control study and 130 cases of newly diagnosed subclinical hypothyroidism from the medical and endocrine OPD  were selected which were divided in two groups based on TSH range: SCH (5.5-10μIU/ml) & Euthyroid subjects(TSH -Normal) to compare the findings. All the patients of age >18 years were included in the study. Those patients were excluded from the study who were having thyroid disease, diabetes, hypertension and any cardiovascularrisk and patients on thyroxine, hypolipidemic drugs or drugs causing dyslipidemia were also excluded. Thyroid profile, lipid profile and qualitative CRP (positive and negative) were estimated in all the participants of study group by taking fasting samples. Thyroid stimulating hormone (TSH), T3 & T4 were measured by using enzyme linked immunosorbant assay (ELISA) technique and the patients with TSH range(>5.5μIU/ml), T3 & T4 within reference range were said to having SCH. CIMT was measured by recording ultra sonographic images of both the left and right common carotid artery with a 12MHz linear array transducer. Patients were examined in the supine position, with the head turned 45° from the side during the scanning procedure. The reference point for the measurement of IMT was the beginning of the dilatation of the carotid bulb, with loss of the parallel configuration of the near and far walls of the common carotid artery. The mean IMT of the four measurements was calculated in each patient. Total cholesterol (<200 mg/dl), Triglycerides (<150 mg/dl) and High-density lipoprotein cholesterol (40-60 mg/dl) were measured by using CHOD/POD method, GPO-PAP method, and CHODPOD/ Phospho tungustate method respectively. LDL cholesterol (<130 mg/dl) was estimated by Friedewald formula. Total cholesterol/ HDL-C and LDL-C/HDL-C ratio were also calculated by dividing TC and LDL-C with HDL-C respectively.

 

RESULTS

Table 1: Profile of categorical parameters with respect to Thyroid status

Parameter

Thyroid Status

P Value

Euthyroid

Subclinical Hypothyroid

Total

No.

%

No.

%

No.

%

Age Category

<=30 Years

10

41.7%

14

58.3%

24

18.5%

.380

31-40 Years

6

40.0%

9

60.0%

15

11.5%

41-50 Years

34

49.3%

35

50.7%

69

53.1%

51-60 Years

11

68.8%

5

31.3%

16

12.3%

>60 Years

4

66.7%

2

33.3%

6

4.6%

Total

65

50.0%

65

50.0%

130

100.0%

Smoking

No

39

50.0%

39

50.0%

78

60.0%

1.00

Yes

26

50.0%

26

50.0%

52

40.0%

Total

65

50.0%

65

50.0%

130

100.0%

Sex

Female

36

50.7%

35

49.3%

71

54.6%

.860

Male

29

49.2%

30

50.8%

59

45.4%

Total

65

50.0%

65

50.0%

130

100.0%

Residence

Rural

40

50.6%

39

49.4%

79

60.8%

.857

Urban

25

49.0%

26

51.0%

51

39.2%

Total

65

50.0%

65

50.0%

130

100.0%

The study shows an equal distribution of euthyroid and subclinical hypothyroid cases (50% each) among 130 participants. No statistically significant association was found between thyroid status and age, smoking, sex, or residence (p > 0.05 for all variables).Above table shows that the SCH group and Euthyroid group was comparable on parameter of age distribution, smoking, sex and residential status

 

Table 2: Profile of continuous parameters with respect to Thyroid Status

Parameter

Thyroid Status

P Value

Euthyroid

Subclinical Hypothyroid

Total

Mean (SD)

Mean (SD)

Mean (SD)

Age (years)

45.55±10.35

42.22±9.63

43.88±10.10

.062

BMI

23.24±1.77

24.36±1.58

23.80±1.77

.001

Total Cholesterol (mg/dl)

186.48±16.50

243.55±19.05

215.02±33.70

<.001

Triglyceride (mg/dl)

144.43±8.05

154.05±7.59

149.24±9.17

<.001

LDL (mg/dl)

125.23±6.63

145.23±9.39

135.23±12.90

<.001

HDL (mg/dl)

49.71±3.67

41.29±3.37

45.50±5.49

<.001

VLDL (mg/dl)

19.40±2.24

25.38±3.80

22.39±4.32

<.001

TC/HDL

3.78±.47

5.94±.73

4.86±1.25

<.001

LDL/HDL

2.53±.24

3.54±.41

3.04±.61

<.001

CIMT (mm)

0.49±0.07

0.83±0.05

0.66±0.18

<.001

T3 (ng/ml)

1.37±.37

1.40±.37

1.38±.37

.637

T4 (mcg/ml)

9.89±2.58

10.05±2.81

9.97±2.69

.694

TSH (μIU/ml)

3.74±.63

7.35±.92

5.54±1.97

<.001

CRP (mg/dl)

0.88±0.66

2.02±0.89

1.45±0.97

<.001

Subclinical hypothyroid patients showed significantly higher BMI, lipid profile (TC, LDL, TG, VLDL), TC/HDL, LDL/HDL ratios, CIMT, TSH, and CRP levels compared to euthyroid individuals (p < 0.001 for most parameters). No significant difference was observed in age, T3, or T4 levels between the groups (p > 0.05).Above table shows that mean age, T3 ,T4 was comparable in SCH group and Euthyroid group whereas mean BMI, TC,TG,LDL,VLDL, TC/HDL, LDL/HDL, CIMT, and CRP was significantly higher in SCH group as compared to Euthyroid group.

Table 3: Correlation of various parameters with TSH

Parameter

Correlation coefficient

P Value

BMI

.360

<.001

Total Cholesterol (mg/dl)

.750

<.001

Triglyceride (mg/dl)

.420

<.001

LDL (mg/dl)

.696

<.001

HDL (mg/dl)

-.711

<.001

VLDL (mg/dl)

.617

<.001

TC/HDL

.784

<.001

LDL/HDL

.761

<.001

CIMT (mm)

.857

<.001

T3 (ng/ml)

-.026

.773

T4 (mcg/ml)

-.019

.832

CRP (mg/dl)

.542

<.001

The data shows significant positive correlations between BMI, lipid profile components, and CIMT, with the strongest correlation observed for CIMT (r = .857, *p* < .001). T3 and T4 levels showed no significant correlation, indicating minimal association with the measured parameters. Above table shows that TSH level was significantly associated with TC,TG, LDL, HDL,VLDL, TC/HDL, LDL/HDL, CRP and CIMT.

DISCUSSION

Hypothyroidism is one of the significant common causes of hyperlipidemia which is linked to atherosclerosis. Nature and degree of dyslipidemia in overt hypothyroidism has been demonstrated in many studies and there is no doubt about the beneficial effects of thyroid substitution on serum lipids and on the risk for cardiovascular diseases10. Although the relationship between SCH and an atherogenic lipoprotein profile is still under debate, a meta-analysis of 13 intervention studies showed that levothyroxine therapy led to a significant reduction in both serum total cholesterol and LDL cholesterol levels11.

 

The study assessed thyroid status distribution across various demographic factors among 130 individuals, equally divided between euthyroid and subclinical hypothyroid groups. Age-wise, the highest proportion of participants (53.1%) were in the 41–50 years category, with no significant association between age and thyroid status (p = .380). Smoking status also showed no association with thyroid condition (p = 1.00), as both smokers and non-smokers were evenly split. Gender and residence type similarly demonstrated no significant relationship with thyroid status, with p values of .860 and .857, respectively. Overall, thyroid status was independent of age, sex, smoking, and rural-urban distribution in this cohort. In present study the CIMT was significantly higher in SCH group as compared to Euthyroid dysfunction. Unal E et al.(2016)12,  Rastgooye Haghi A et al.(2017)13 and Tan M et al.(201914]in their study found that CIMT was significantly higher in SCH group as compared to Euthyroid dysfunction which is consistent with results of present study.

 

The comparison of biochemical and clinical parameters between euthyroid and subclinical hypothyroid individuals revealed significant differences across most markers. Subclinical hypothyroid individuals had higher BMI (24.36 vs. 23.24, p = .001), lipid levels, and atherogenic ratios, including total cholesterol, LDL, VLDL, and TC/HDL, all with p < .001. HDL levels were significantly lower in the subclinical hypothyroid group (41.29 vs. 49.71, p < .001). CIMT was notably elevated in subclinical hypothyroid individuals (0.83 mm vs. 0.49 mm, p < .001), indicating a higher cardiovascular risk. T3 and T4 levels showed no significant differences between groups, while TSH was markedly higher in the subclinical group (p < .001). Additionally, CRP, a marker of inflammation, was significantly elevated in subclinical hypothyroid individuals (2.02 vs. 0.88, p < .001).Subclinical hypothyroidism has a major influence on derangement of lipid profile leading to early atherosclerosis. One of the largest study, the Colorado study conducted on thyroid dysfunction also showed that there is derangement of lipid profile with increasing TSH values15. Tanis et al also concluded that SCH is independently associated with atherosclerosis and cardiovascular morbidity which can be attributed to dyslipidemia and substitution with exogenous thyroid replacement reverses the lipid changes16.Monzani et al also showed that the SCH group had higher CIMT values as compared to Euthyroid group17. Nagasaki et al18 and Kim et al (2009)19 also found the similar association in their study and found  significantly higher CIMT values in hypothyroid and SCH group as compared to control group and replacement with thyroxine decreased the CIMT values on follow up.

However, not all researches showed an association between TSH and CIMT. In the study of Chiche et al.20among a population of hyperlipidemic patient’s investigators found that neither prevalence nor severity of carotid plaques nor CIMT were significantly different between hypothyroid patients and controls. Similarly Chiche F et al. in their study found that subclinical hypothyroid patients have normal CIMT20.

 

LIMITATIONS

  1. This investigation was done on a sample of modest size in a single center; therefore, the effects of modest sample size should be considered while generalizing the results.
  2. TPO antibodies were not examined in the group as these antibodies significantly increased the risk of cardiovascular morbidity and have different effects on body organs.
CONCLUSION

The present study have concluded that subclinical hypothyroidism is associated with an atherogenic lipid. Subclinical hypothyroidism is characterized by an increase in concentration of total cholesterol, LDL and triglycerides and by decrease in HDL levels.  There might be a potential link between subclinical hypothyroidism and atherosclerosis which was further strengthened by the fact that this study also found a positive significant association of increased CIMT and CRP

REFERENCES
  1. Franzoni F, Galetta F, Fallahi P, Tocchini L, Braccini L, Rossi M, Carpi A, Santoro G, Antonelli A. Carotid integrated backscatter analysis in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2007;68(2):278–283. doi: 10.1111/j.1365-2265.2007.03035.x. [DOI] [PubMed] [Google Scholar]
  2. Knapp M, Lisowska A, Sobkowicz B, Tycińska A, Sawicki R, Musiał WJ. Myocardial perfusion and intima-media thickness in patients with subclinical hypothyroidism. Adv Med Sci. 2013;58(1):44–49. doi: 10.2478/v10039-012-0068-9. [DOI] [PubMed] [Google Scholar]
  3. Cabral MD, Teixeira P, Soares D, Leite S, Salles E, Waisman M. Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics (Sao Paulo) 2011;66(8):1321–1328. doi: 10.1590/s1807-59322011000800003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Delitala AP, Filigheddu F, Orrù M, AlGhatrif M, Steri M, Pilia MG, Scuteri A, Lobina M, Piras MG, Delitala G, Lakatta EG, Schlessinger D, Cucca F. No evidence of association between subclinical thyroid disorders and common carotid intima medial thickness or atherosclerotic plaque. Nutr Metab Cardiovasc Dis. 2015;25(12):1104–1110. doi: 10.1016/j.numecd.2015.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar].
  5. Jeong SK, Seo JY, Nam HS, Park HK. Thyroid function and internal carotid artery stenosis in ischemic stroke. Endocr J. 2010;57(8):711–718. doi: 10.1507/endocrj.k10e-135. [DOI] [PubMed] [Google Scholar]
  6. Monzani F, Caraccio N, Kozàkowà M, Dardano A, Vittone F, Virdis A, Taddei S, Palombo C, Ferrannini E. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab. 2004;89(5):2099–2106. doi: 10.1210/jc.2003-031669.
  7. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160: 526–534.
  8. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90: 581–585; discussion 586–587. pmid:15643019.
  9. Jorde R, Joakimsen O, Stensland E, Mathiesen EB. Lack of significant association between intima-media thickness in the carotid artery and serum TSH level. The Tromsø Study. Thyroid. 2008;18(1):21–25. doi: 10.1089/thy.2007.0165.
  10. Asvold BO, Vatten L et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study, Eur J Endocrinol, 2007;156: 181-186.
  11. Cooper DS, Halpern R et al. Thyroxine therapy in subclinical hypothyroidism. A double-blind placebo-controlled trial. Ann Intern Med 1984; 101:18–24.
  12. Unal E, Akın A, Yıldırım R, Demir V, Yildiz İ, Haspolat YK. Association of Subclinical Hypothyroidism with Dyslipidemia and Increased Carotid Intima-Media Thickness in Children. J Clin Res Pediatr Endocrinol. 2017 Jun 1;9(2):144-149. doi: 10.4274/jcrpe.3719. Epub 2016 Dec 23. PMID: 28008862; PMCID: PMC5463287.
  13. Rastgooye Haghi A, Solhjoo M, Tavakoli MH. Correlation Between Subclinical Hypothyroidism and Dyslipidemia. Iran J Pathol. 2017 Spring;12(2):106-111. Epub 2017 Apr 1. PMID: 29515631; PMCID: PMC5831065.
  14. Tan M, Korkmaz H, Aydın H, Kumbul Doğuç D. FABP4 levels in hypothyroidism and its relationship with subclinical atherosclerosis. Turk J Med Sci. 2019 Oct 24;49(5):1490-1497. doi: 10.3906/sag-1904-41. PMID: 31651119; PMCID: PMC7018356.
  15. Canaris, G.J.; Manowitz, N.R.; Mayor, G.; Ridgway, E.C. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 2000, 160, 526.
  16. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: A reanalysis of intervention studies. Clin Endocrinol. 1996;44:643–9. doi: 10.1046/j.1365-2265.1996.739560.x.
  17. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab. 2004;89: 2099–2106. pmid:15126526.
  18. Nagasaki T, Inaba M et al, 2003 Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid function Clin Endocrinol (Oxf) 59:607–612.
  19. Kim SK, Kim SH, Park KS, Park SW, Cho YW. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement. Endocr J.2009;56:753–758.

Chiche F, Jublanc C, Coudert M, Carreau V, Kahn JF, Bruckert E. Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients. Atherosclerosis. 2009; 203:269–276

Recommended Articles
Research Article
Anterolateral and Posterior Approach for the Surgical Management of Thoracolumbar Spine Fracture: A Systematic Review
...
Published: 19/03/2023
Research Article
Development and Validation of an Albumin–Electrolyte-Based Risk Score for Predicting In-Hospital Mortality in Elderly COVID-19 Patients: A Retrospective Cohort Study from SLN MCH Koraput
...
Published: 31/07/2025
Research Article
A Cross Sectional Study on Prevalence of Sarcopenia in Patients with Type 2 Diabetes Mellitus
...
Published: 30/07/2025
Research Article
Study of Porosity of Bone and Its Relation to Fractures around Hip
...
Published: 29/07/2025
Chat on WhatsApp
© Copyright Journal of Contemporary Clinical Practice